These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1706098)

  • 1. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients.
    Heikkilä L; Rimón R; Terenius L
    Psychiatry Res; 1990 Dec; 34(3):229-36. PubMed ID: 1706098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment.
    Heikkilä L
    Schizophr Res; 1993 Jan; 8(3):273-7. PubMed ID: 8094631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin).
    Miller C; Kirchmair R; Troger J; Saria A; Fleischhacker WW; Fischer-Colbrie R; Benzer A; Winkler H
    Biol Psychiatry; 1996 Jun; 39(11):911-8. PubMed ID: 9162202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
    Romain JL; Dermain P; Greslé P; Grignon S; Moisan P; Nore D; Pech G; Benyaya J; Perret I
    Encephale; 1996; 22(4):280-6. PubMed ID: 9035983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics.
    Chin CN; Hamid AR; Philip G; Ramlee T; Mahmud M; Zulkifli G; Loh CC; Zakariah MS; Norhamidah MS; Suraya Y; Roslan KA; Chandramohan P; Cheah YC; Leonard AO
    Med J Malaysia; 1998 Dec; 53(4):365-71. PubMed ID: 10971979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.
    Wistedt B; Koskinen T; Thelander S; Nerdrum T; Pedersen V; Mølbjerg C
    Acta Psychiatr Scand; 1991 Jul; 84(1):14-21. PubMed ID: 1681680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia.
    Kazi HA
    Pharmatherapeutica; 1986; 4(9):555-60. PubMed ID: 3763650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower CSF level of dynorphin(1-8) immunoreactivity in schizophrenic patients.
    Zhang AZ; Zhou GZ; Xi GF; Gu NF; Xia ZY; Yao JL; Chang JK; Webber R; Potkin S
    Neuropeptides; 1985 Feb; 5(4-6):553-6. PubMed ID: 2860611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia.
    Sasayama D; Hattori K; Teraishi T; Hori H; Ota M; Yoshida S; Arima K; Higuchi T; Amano N; Kunugi H
    Schizophr Res; 2012 Aug; 139(1-3):201-6. PubMed ID: 22742979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales.
    Bobon D; Troisfontaines B; Kempeneers JL; Xhenseval B; Bourdouxhe S; Mirel J; Gilson H; Toussaint C; von Frenckell R; Pedersen V
    Acta Psychiatr Belg; 1986; 86(2):152-76. PubMed ID: 2873713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls.
    Beckmann H; Reynolds GP; Sandler M; Waldmeier P; Lauber J; Riederer P; Gattaz WF
    Arch Psychiatr Nervenkr (1970); 1983; 232(6):463-71. PubMed ID: 6134517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients.
    Katila H; Hurme M; Wahlbeck K; Appelberg B; Rimón R
    Neuropsychobiology; 1994; 30(1):20-3. PubMed ID: 7969854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopenthixol decanoate in the treatment of chronic schizophrenic in-patients.
    Viswanathan R; Rajhkowa S
    Pharmatherapeutica; 1982; 3(2):93-9. PubMed ID: 7100227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment.
    Reinikainen KJ; Koponen H; Jolkkonen J; Riekkinen PJ
    Psychiatry Res; 1990 Sep; 33(3):307-12. PubMed ID: 2243905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients--a double-blind clinical multicentre investigation.
    Heikkilä L; Laitinen J; Vartiainen H
    Acta Psychiatr Scand Suppl; 1981; 294():30-8. PubMed ID: 7041517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate.
    Szukalski B; Lipska B; Welbel L; Nurowska K
    Psychopharmacology (Berl); 1986; 89(4):428-31. PubMed ID: 2875481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels.
    Solgaard T; Kistrup K; Aaes-Jørgensen T; Gerlach J
    Pharmacopsychiatry; 1994 May; 27(3):119-23. PubMed ID: 8078952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
    Beinfeld MC; Garver DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):601-9. PubMed ID: 1956989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.